Walking assessment after lumbar puncture in normal-pressure hydrocephalus: a delayed improvement over 3 days

Roman Schniepp, MD,1,2 Raimund Trabold, MD,3 Alexander Romagna, MD,3 Farhoud Akrami,2 Kristin Hesselbarth,2 Max Wuehr, PhD,2 Aurelia Peraud, MD,3 Thomas Brandt, MD,2,4 Marianne Dieterich, MD,1,2 and Klaus Jahn, MD2,5

1Department of Neurology, 2German Center for Vertigo and Balance Disorders, 3Department of Neurosurgery, 4Institute for Clinical Neuroscience, Ludwig-Maximilians University Munich; and 5Schoen Klinik, Bad Aibling, Bavaria, Germany

OBJECTIVE The determination of gait improvement after lumbar puncture (LP) in idiopathic normal-pressure hydrocephalus (iNPH) is crucial, but the best time for such an assessment is unclear. The authors determined the time course of improvement in walking after LP for single-task and dual-task walking in iNPH.

METHODS In patients with iNPH, sequential recordings of gait velocity were obtained prior to LP (time point [TP]0), 1–8 hours after LP (TP1), 24 hours after LP (TP2), 48 hours after LP (TP3), and 72 hours after LP (TP4). Gait analysis was performed using a pressure-sensitive carpet (GAITRite) under 4 conditions: walking at preferred velocity (STPS), walking at maximal velocity (STMS), walking while performing serial 7 subtractions (dual-task walking with serial 7 [DTS7]), and walking while performing verbal fluency tasks (dual-task walking with verbal fluency [DTVF]).

RESULTS Twenty-four patients with a mean age of 76.1 ± 7.8 years were included in this study. Objective responder status moderately coincided with the self-estimation of the patients with subjective high false-positive results (83%). The extent of improvement was greater for single-task walking than for dual-task walking (p < 0.05). Significant increases in walking speed were found at TP2 for STPS (p = 0.042) and DTVF (p = 0.046) and at TP3 for STPS (p = 0.035), DTS7 (p = 0.042), and DTVF (p = 0.044). Enlargement of the ventricles (Evans Index) positively correlated with early improvement. Gait improvement at TP3 correlated with the shunt response in 18 patients.

CONCLUSIONS Quantitative gait assessment in iNPH is important due to the poor self-evaluation of the patients. The maximal increase in gait velocity can be observed 24–48 hours after the LP. This time point is also best to predict the response to shunting. For dual-task paradigms, maximal improvement appears to occur later (48 to 72 hours). Assessment of gait should be performed at Day 2 or 3 after LP.

http://thejns.org/doi/abs/10.3171/2015.12.JNS151663

KEY WORDS normal-pressure hydrocephalus; gait speed; improvement; lumbar puncture; functional neurosurgery

Diagnosis of idiopathic normal-pressure hydrocephalus (iNPH) was first described in 1965.1 The syndrome is characterized by the clinical triad of gait disturbance, cognitive dysfunction, and urinary symptoms. The prevalence of iNPH reported in selected populations and in community-based studies on adults 18–79 years of age varies between 0.1% and 2.9%.16 It is one of the few neurological diseases in which a gait disorder and/or dementia can improve to a complete remission of symptoms. A disturbed gait is usually the first sign and most disabling symptom.14 Typical features are a diminished gait velocity, a reduced stride length due to the co-contractions of proximal muscles,40 a reduced foot-to-floor clearance (step height) during the swing phase of the gait cycle, and increased balance-related gait measurements such as step width and foot rotation angles.37,39 Such difficulties can improve after the removal of 30–50 ml of cerebrospinal fluid (CSF) via lumbar puncture (LP). Not only is this improvement important for establishing the diagnosis, but it is also one of the few prognostic indicators of suitability for shunt implantation.23 In
patients who strongly respond to LP, their gait pattern often dramatically improves after shunt placement.15

Given the significance of LP in establishing the diagnosis of iNPH, the quantification of gait changes has become clinically important within the last decade. However, many studies on gait changes after LP have used clinical gait scores rather than quantitative gait analysis procedures, resulting in a limited interpretation of their findings. One quantitative study of 10 NPH patients who had undergone LP showed that gait velocity and stride length were the most responsive gait parameters, whereas cadence and balance-related parameters remained unaffected. Authors of that study suggested that an increase in gait velocity by approximately 20% after LP could be considered a relevant improvement.

There is also indirect evidence that the type of quantitative gait examination strongly influences the outcome of the measurement. The importance of measuring dual motor-cognition tasks in patients with mild cognitive impairment or dementia to assess mobility problems is well-established. This method was recently studied in an NPH cohort. The authors showed that patients with iNPH have reduced abilities to perform a motor-cognitive dual task. Moreover, assessing dual-task behavior was equivalent or superior to estimating the LP effect in patients with iNPH.

One pivotal requirement in assessing gait changes after LP is selecting the right time point to make such an assessment. Clearly, gait improvement after LP is a transient phenomenon, and the temporal characteristics for single- and dual-task walking can be different. Evaluating the gait performance of iNPH patients after LP at a time point of maximal improvement is desirable since it would allow an assessment with the highest sensitivity and best predictive value for shunt implantation.

However, there are few data about the time course of gait changes after LP in iNPH. Studies using nonquantitative, examiner-based gait evaluation and quantitative measures have provided evidence of early improvement within the first 24 hours after LP. Other studies have supported the view that gait improvement can be detected more than 24 hours after LP. Clinical standards of care usually include a follow-up assessment immediately after or the same day as the LP, although there is no consensus about the real time course of walking improvement after LP.

Until now, no study has investigated the temporal characteristics of gait improvement by using a sequential protocol of gait assessments over several days after LP. Information about the gradual improvement of gait in the days after LP would allow us to adjust the post-LP measurement to a time of optimal sensitivity for estimating the LP effect and to avoid false-negative results. Thus, we investigated gait improvement after LP over a time span ranging from the day of LP (1–8 hours after LP, Day 1) to Days 2, 3, and 4 after LP. The temporal characteristics of gait improvement after LP were then correlated with the response to shunt surgery and to repeated LP therapy. We further compared the time course of walking improvement while performing single-task walking and while performing dual-task walking in iNPH patients after LP.

**Methods**

**Participants**

Patients in the departments of neurology and neurosurgery at the University Hospital of the Ludwig-Maximilians University Munich were recruited for this prospective study if they fulfilled the following clinical and radiological criteria for iNPH, as proposed by the German Neurological Society guidelines and adapted from Relkin and colleagues: 1) at least 2 clinical signs of the Hakim triad including gait disorder and cognitive dysfunction, 2) enlargement of the lateral ventricles (assessed using the Evans Index [EI] > 0.3) on MRI or CT, 3) an opening CSF pressure < 15 cm H2O, and 4) exclusion of other differential diagnoses. All participants gave their written informed consent to take part in the study. The study was performed according to the guidelines laid down in the Declaration of Helsinki and its later amendments. The local ethics committee approved the study protocol.

All patients enrolled in the study underwent physical and neurological examination including testing for motor, sensory, and basal ganglia disorders. If necessary, additional complementary technical diagnostic procedures were performed, for example, electrophysiological examinations, neuroimaging of the brain or spinal cord, and vestibular testing. Cognition was assessed using either the Mini-Mental State Examination (MMSE) or the Montréal Cognitive Assessment (MoCA).

**Lumbar Puncture Procedures**

If a suspected diagnosis of iNPH could not be rejected, patients underwent an LP procedure, during which 30–50 ml of CSF was removed. Gait performance was evaluated before the LP (time point [TP]0), 1–8 hours after the LP (TP1), 24 hours after LP (TP2), 48 hours after LP (TP3), and 72 hours after LP (TP4).

**Gait Assessment**

Gait performance was measured using a pressure-sensitive carpet system (GAITRite, CIR Systems Inc.) 6.7 m in length with a sampling rate of 120 Hz. Relevant temporal and spatial gait cycle parameters were recorded, but only walking speed was analyzed. The gait analysis procedure involved a protocol of 4 different conditions: 2 speed conditions (single-task preferred walking speed [STPS] and maximal walking speed [STMS]), as well as 2 cognitive dual-task conditions (using working memory while counting backwards, that is, dual-task walking with serial 7 subtractions [DTS7]; and using semantic memory while enumerating animal names, that is, dual-task walking with verbal fluency [DTVF]). Each condition was tested twice. Each walk was started 1.5 m in front of the mat and continued for 1.5 m beyond it to provide steady-state locomotion.

After each recording, patients were asked to evaluate their gait performance (“Do you think that your gait performance has improved after LP?”) by answering “yes” or “no.”

**Data Analysis**

Walking velocity was calculated as the mean of the 2
recordings for each condition. Matlab (The Mathworks Inc.) and SPSS (SPSS Institute Inc.) were used for data analysis. To quantify the relative change in walking speed after LP, a variation rate (VR) was calculated using the following formula:

\[
\text{VR} = \frac{\text{parameter after LP} - \text{parameter before LP}}{\text{parameter before LP}} \times 100.
\]

The effects of the dependent variable were analyzed using a 2-way repeated measurement (rm) ANOVA and a Bonferroni post hoc analysis, with time points (TP1, TP2, TP3, TP4) and gait conditions (STPS, STMS, DTS7, DTVF) as factors. Significant interaction effects were further broken down into simple main effects, and the covariates of age, sex, height, and leg length were included in the model. Correlations were calculated using Pearson’s and Kendall-Tau procedures. The results were considered significant at \( p < 0.05 \). Contingency between the self-evaluation of gait improvement and improvement according to objective gait measures was analyzed using chi-square tests.

### Results

#### Demographic Information and Clinical Features

Twenty-four patients, 7 female and 17 male, were included in the study. Their mean age was 76.1 ± 7.8 years, and the mean duration of the gait disorder was 35 ± 26 months (Table 1). All patients showed gait impairments typical of iNPH and had cognitive dysfunction (score below 25 points on the MMSE or below 26 points on the MoCA). Twenty patients had bladder dysfunction. Computed tomography or MRI revealed a mean EI of 0.39 ± 0.05, and each patient had an EI > 0.3. The mean time period between LP and gait analysis was 3.2 ± 2.7 hours for TP1, 21.3 ± 4.8 hours for TP2, 53.7 ± 6.4 hours for TP3, and 74.3 ± 9.9 hours for TP4.

Measurement of the opening pressure after LP revealed that the intracranial pressure was below 15 cm H\(_2\)O for each patient. A ventriculoperitoneal shunt was placed in 10 patients at 3–12 months after the LP. All of these patients reported sustained improvement in walking performance at 3–12 months after surgery. Eight patients were treated with repeated LPs at intervals of 3–6 months. Six patients refused any further invasive treatment, for example, repeated LPs or shunt insertion. Four of those patients were treated pharmacologically with l-dopamine and memantine. Follow-up measurements of walking capacity were performed in all patients; the follow-up period ranged from 3 months to a maximum of 12 months (2 persons without invasive treatment).

#### Relationship Between Subjective and Objective Measures

The rmANOVA model did not show significant differences in the walking characteristics between the groups of “subjective responders” (patients who answered “yes” to the question, “Do you think that your gait performance has improved after LP?”) and “subjective nonresponders” (patients who answered “no”).

A maximum of 18 “objective responders” to LP (patients who had improvement in their gait after LP according to objective measures [pressure-sensitive carpet system]) had ≥ 20% improvement in walking speed (in at least 1 condition, compared with baseline) in at least 1 post-LP measurement. Table 2 summarizes the contingency and diversity of the self-evaluation and technically based gait evaluation. Chi-square tests were not significant (\( p = 0.437, \text{chi-square} = 0.605 \)). Thirty-three percent (6 of 18) of the patients with significant objectively measured gait improvements estimated that they had a (false) negative result, whereas 83% (5 of 6) of the patients without significant gait improvement estimated that they had an improvement in gait (false-positive). Only 4 patients reported an immediate improvement at TP1. Fourteen patients reported an improved gait at TP2, 17 patients at TP3, and 12 patients at TP4 (Table 3).

Nine of the 17 subjective responders underwent shunt implantation; 1 patient who did not subjectively improve (but showed an increased walking speed during gait analysis) underwent surgery 10 months after LP.

#### Table 1. Demographic and clinical characteristics of 24 patients with iNPH

<table>
<thead>
<tr>
<th>Variable</th>
<th>No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic demographic information</td>
<td></td>
</tr>
<tr>
<td>Females/males</td>
<td>7:17</td>
</tr>
<tr>
<td>Mean age in yrs</td>
<td>76 ± 8</td>
</tr>
<tr>
<td>Mean height in m</td>
<td>1.74 ± 0.12</td>
</tr>
<tr>
<td>Mean duration of symptoms in yrs</td>
<td>35.4 ± 25.7</td>
</tr>
<tr>
<td>Clinical feature</td>
<td></td>
</tr>
<tr>
<td>Patients w/ gait disorder</td>
<td>24</td>
</tr>
<tr>
<td>Patients w/ bladder dysfunction</td>
<td>20</td>
</tr>
<tr>
<td>Patients w/ cognitive dysfunction</td>
<td>24</td>
</tr>
<tr>
<td>Mean MMSE score</td>
<td>22.4 ± 3.2</td>
</tr>
<tr>
<td>Mean MoCA score</td>
<td>21.5 ± 3.1</td>
</tr>
<tr>
<td>Mean ICP pressure in cm H(_2)O at LP (range)</td>
<td>10.4 (7–14)</td>
</tr>
<tr>
<td>Mean concomitant diseases (CCI) in points</td>
<td>12.3 ± 4.2</td>
</tr>
<tr>
<td>Neuroimaging</td>
<td></td>
</tr>
<tr>
<td>Patients w/ MRI</td>
<td>18</td>
</tr>
<tr>
<td>Patients w/ CT</td>
<td>6</td>
</tr>
<tr>
<td>Mean EI</td>
<td>0.39 ± 0.05</td>
</tr>
<tr>
<td>Therapy</td>
<td></td>
</tr>
<tr>
<td>Patients w/ shunt placement</td>
<td>10</td>
</tr>
<tr>
<td>Patients w/ repeated LP</td>
<td>8</td>
</tr>
<tr>
<td>Patients w/ no CSF therapy</td>
<td>6</td>
</tr>
</tbody>
</table>

CCI = Charlson Comorbidity Index; ICP = intracranial pressure.

#### Table 2. Contingency table for self-evaluation versus objective gait analysis

<table>
<thead>
<tr>
<th>Objective Gait Assessment</th>
<th>Self-Evaluation</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Improved (≥20%)</td>
<td>12</td>
<td>6</td>
</tr>
<tr>
<td>Not improved (&lt;20%)</td>
<td>5</td>
<td>1</td>
</tr>
</tbody>
</table>

FN = false negative; FP = false positive; TN = true negative; TP = true positive.
Temporal Consistency of the Gait Measures

Individual comparisons of the objective responder status at each time point revealed a high inter-subject consistency of the data. Table 3 summarizes the absolute numbers of objective responders and the patients who switched (called “converters”) from responder to nonresponder status or vice versa between the subsequent time points. Converters from nonresponder to responder status were mainly observed between TP1, TP2, and TP3, according to the idea of gradual gait improvement after LP. Converters from responder to nonresponder status were mainly observed between TP3 and TP4, indicating a weakening of the LP effect after 48 hours. No patients switched the responder status more than 1 time within the 3 days after measurement. A maximum of 2 patients converted from responder to nonresponder status between TP2 and TP3 for the condition of STMS (only 1 of those also at the other conditions).

Dual-Task Performance

Walking speeds during DTS7 (F = 4.467, p = 0.024) and DTVF (F = 4.239, p = 0.028) were significantly decreased compared with those during STPS (at TP0). These differences remained at TP1 and TP2 but diminished at TP3 and TP4. The mean dual-task costs (that is, the percentage decrease in walking speed during dual-task walking) were −28.5% ± 18.9% for DTS7 and −28.1% ± 15.8% for DTVF at TP0.

There were no correlations between baseline walking performance and the individual dual-task costs, but there was a strong correlation between the individual dual-task costs for both dual tasks (R² = 0.94, p < 0.001).

Walking Velocities After LP

In the rmANOVA model, there was a significant increase in walking velocity after LP for the walking conditions of STPS, DTS7, and DTVF (Table 4). Bonferroni post hoc analysis of the interaction effect (walking condition × time point) revealed a significant increase in walking speed (compared with TP0) at TP2 for STPS (F = 3.96, p = 0.042) and for DTVF (F = 3.52, p = 0.046). At TP3, there were significant increases in walking speed (compared with TP0) for STPS (F = 4.11, p = 0.035), for DTS7 (F = 3.98, p = 0.042), and for DTVF (F = 3.76, p = 0.044).

The rmANOVA model of the VRs in walking speed revealed a significant increase after LP for all 4 walking conditions (Table 4 and Fig. 1).

Evans Index and Gait Performance in iNPH

The EIs of the iNPH patients were increased (mean of 0.39, range 0.32–0.45); thus, every patient met the criterion of ventricle enlargement (EI > 0.30). There was no significant correlation between the EIs and the absolute values of gait velocity at any time point of the gait measurements. Significant positive correlations for STPS and STMS were found for the VRs in walking speed. The EIs positively correlated with the VRs in walking speed at TP1 for STPS (R² = 0.693, p = 0.0001; Fig. 2) and for STMS (R² = 0.406, p = 0.049). At TP2, there was a positive correlation between the VRs in walking speed and the EIs for STPS only (R² = 0.612, p = 0.001; Table 5).

Relationship Between LP Response and Therapeutic Outcome

The improvement in walking speed after therapy significantly depended on the therapeutic option chosen. The greatest improvement in walking speed was found for shunt surgery (for example, 34.7% ± 11.1% for STPS), followed by the repeated LP strategy (for example, 17.2% ± 18.8% for STPS). Patients who refused further CSF removal showed a gradual decrease in walking speed (for example, −28.1% ± 13.2% for STPS). The administration of dopamine and memantine did not completely reverse this decline (for example, −16.2% ± 6.2% for STPS). Parallel results were present in the other walking conditions (Supplemental Table 1). Post hoc analysis of the rmANOVA model showed that shunt surgery and repeated LPs led to significantly greater improvements in gait velocity compared with those in patients without CSF removal (p < 0.05). The response to LP correlated with improvement after shunt surgery and under repeated CSF removals. However, correlations between the VRs in walking speed improvement after LP and the VRs in walking speed improvement under CSF removal therapy (either shunt or repeated LPs) were only significant for delayed time points at TP3 (for STPS, for STMS, and for DTS7, all p < 0.05; Supplemental Table 2). No correlation was found for the EIs and gait improvements during follow-up.

Discussion

This study provides the first evidence of a delayed change in gait speed in patients with iNPH during the first 3 days after LP. Our main findings are as follows: 1) A reduction in gait velocity is a key feature of the iNPH gait disorder, and the removal of CSF improves walking ve-
2) Significant improvements in walking speed were identified 24–48 hours after LP (maximum). 3) Ventricular enlargement correlated with a relative improvement in walking speed in the early phase after LP. 4) The amount of walking improvement 48–72 hours after LP correlated with the benefit from CSF removal therapy (shunt or repeated LP).

Gait Assessment as a Key Procedure for LP and iNPH

Clinical and radiological signs of iNPH are fundamental for establishing a diagnosis of iNPH and selecting can-

<table>
<thead>
<tr>
<th>Condition</th>
<th>TP0</th>
<th>TP1</th>
<th>TP2</th>
<th>TP3</th>
<th>TP4</th>
<th>rmANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Walking velocity (m/sec)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STPS</td>
<td>0.59 ± 0.09</td>
<td>0.64 ± 0.10</td>
<td><strong>0.72 ± 0.11</strong></td>
<td><strong>0.77 ± 0.09</strong></td>
<td>0.64 ± 0.11</td>
<td>F4, 23 = 3.04, p &lt; 0.020</td>
</tr>
<tr>
<td>STMS</td>
<td>0.93 ± 0.20</td>
<td>0.99 ± 0.21</td>
<td>1.00 ± 0.19</td>
<td>1.09 ± 0.21</td>
<td>0.97 ± 0.22</td>
<td>F4, 23 = 0.82, p = NS</td>
</tr>
<tr>
<td>DTS7</td>
<td>0.42 ± 0.09</td>
<td>0.47 ± 0.12</td>
<td>0.52 ± 0.11</td>
<td><strong>0.58 ± 0.09</strong></td>
<td>0.54 ± 0.10</td>
<td>F4, 23 = 2.71, p &lt; 0.048</td>
</tr>
<tr>
<td>DTVF</td>
<td>0.41 ± 0.06</td>
<td>0.46 ± 0.10</td>
<td><strong>0.53 ± 0.13</strong></td>
<td><strong>0.58 ± 0.12</strong></td>
<td>0.54 ± 0.11</td>
<td>F4, 23 = 2.72, p &lt; 0.048</td>
</tr>
<tr>
<td>VRs for walking velocity (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STPS</td>
<td>—</td>
<td>12.1 ± 6.0</td>
<td><strong>26.2 ± 17.5</strong></td>
<td><strong>36.8 ± 13.6</strong></td>
<td>12.5 ± 13.3</td>
<td>F3, 23 = 3.85, p &lt; 0.012</td>
</tr>
<tr>
<td>STMS</td>
<td>—</td>
<td>7.5 ± 11.1</td>
<td>10.5 ± 15.6</td>
<td><strong>20.3 ± 22.5</strong></td>
<td>6.2 ± 19.5</td>
<td>F3, 23 = 3.21, p &lt; 0.020</td>
</tr>
<tr>
<td>DTS7</td>
<td>—</td>
<td>14.3 ± 11.5</td>
<td><strong>32.3 ± 20.5</strong></td>
<td><strong>52.1 ± 15.9</strong></td>
<td><strong>43.6 ± 24.6</strong></td>
<td>F3, 23 = 3.25, p &lt; 0.018</td>
</tr>
<tr>
<td>DTVF</td>
<td>—</td>
<td>10.9 ± 24.4</td>
<td>36.4 ± 26.6</td>
<td><strong>50.4 ± 21.4</strong></td>
<td><strong>40.2 ± 24.2</strong></td>
<td>F3, 23 = 2.85, p &lt; 0.042</td>
</tr>
</tbody>
</table>

NS = not significant, p > 0.05.

* The effect of removing 40 ml of CSF on the walking velocity of patients with iNPH. Values expressed as the mean ± standard deviation of the raw values for gait speed and the percentage improvement in gait speed over a time span of 90 hours after LP. Boldface type indicates a significant post hoc Bonferroni correction for the time point.

FIG. 1. Time course of relative changes in walking speed after LP. Mean values with upper and lower quartiles of the percentage improvement (VRs) in walking speed following the LP procedure, which involved the removal of 30–50 ml of CSF. Figure is available in color online only.
candidates for shunt placement. A positive response to LP is the most common clinical sign used to verify the diagnosis and to predict a beneficial outcome of shunt surgery. Quantitative gait assessment helps by providing standardized and comparable data for the clinician. The importance of such quantitative measures for evaluating LP is further stressed by the low reliability of patient self-evaluations. Only 54% of the patients had subjective outcomes consistent with the objective gait measures. Obviously, there is a strong tendency to subjectively overestimate gait performance after LP. Increased levels of motivation and the anticipation of possible treatment options after a positive LP outcome could lead to such false-positive self-evaluations. Since a positive LP outcome serves as a strong argument for shunt insertion in iNPH, clinicians should assess gait in an objective way to avoid false-positive evaluations of the LP procedure.

While the patient’s appraisal of an improvement in gait after LP is decisive in delivering treatment for iNPH, it is still subject to false results. Quantitative gait measures, however, provide objective measures of the clinical outcome that could be used to identify false-positive responders and avoid exposing this subgroup to surgical risks.

Walking Speed Reduction as a Key Aspect of the iNPH Gait Disorder

It has been demonstrated that a reduced walking pace is a key feature of the gait disorder in patients with iNPH. This clinical hallmark can be easily assessed. In agreement with previous studies, the iNPH cohort in the current study showed a preferred walking pace that was approximately 50% of the walking pace of healthy subjects. Reduced walking speed is a key feature of mobility impairments and has been linked to a decreased quality of life, decreased mobility, and impaired everyday independence of elderly persons. Stolze et al. suggested that an improvement in walking speed after LP by ≥ 20% could be considered a relevant improvement. This threshold was used in the present study to define the objective responder status, and the maximum average walking speed improvement was 37% at TP2 for STPS. During STMS, the percentage of improvement was lower. Thus, patients with iNPH increased their self-selected walking pace, but their maximal speed capacity was only slightly improved.

Dual-Task Performance of Patients With iNPH

Currently, postural control is believed to share attentional resources with cognition. Dual-task paradigms—that is, the simultaneous tasks of walking and cognition—have been used to shed light on motor and cognitive interference during gait. The walking and cognitive functions of patients with iNPH are known to be independently improved after LP. In a recent study, spatiotemporal gait parameters assessed during dual-task walking were shown to be a good discriminator of responders versus nonresponders in patients with iNPH after LP.

Our results support and extend these findings, showing that 22 of 24 patients with iNPH walked more slowly during the dual task than during the single task. The average dual-task cost of approximately 28% is comparable to findings reported in a recent study and other clinical cohorts.

The comparison of dual-task costs between the serial 7 task and the verbal fluency task shows a strong inter-task correlation; thus, the type of cognitive task is not relevant for the result of the dual-task gait assessment. Instead, impaired dual-task performance reflects a disturbance in higher-level processing domains (for example, attention-

<table>
<thead>
<tr>
<th>Condition</th>
<th>TP0</th>
<th>TP1</th>
<th>TP2</th>
<th>TP3</th>
<th>TP4</th>
</tr>
</thead>
<tbody>
<tr>
<td>EI &amp; walking speed</td>
<td>STPS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>STMS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>DTS7</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>DTVF</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>EI &amp; VRs in walking speed</td>
<td>STPS</td>
<td>—</td>
<td>0.693, p = 0.000</td>
<td>0.612, p = 0.001</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>STMS</td>
<td>—</td>
<td>0.406, p = 0.049</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>DTS7</td>
<td>—</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td></td>
<td>DTVF</td>
<td>—</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>

* Results of Pearson’s correlation procedures of individual EIs and gait velocities and the improvement in gait velocities (expressed in VRs).
with iNPH who had undergone CSF removal therapies, ei
tervention enlargement alone cannot explain the dual-task
impairments in iNPH. Metabolic, vascular, or other dis-
turbances of deep white matter in the frontal brain regions
may explain the dual-task problems of patients with iNPH;
however, our study design does not allow us to speculate
on any underlying pathophysiological mechanisms. Fur-
ter studies using more sophisticated neuroimaging tech-
niques are necessary to investigate brain structure and/or
function relationships in iNPH.

Analysis of the improvement in walking speed after
LP revealed greater relative improvements for dual-task
walking than for single-task walking. However, this effect
may be a result of the lower baseline values of gait speed
at TP0. In contrast to the earlier findings of Allali et al.,
our absolute improvements for single-task walking were
higher than those for dual-task walking. In particular, for
a clinical setup, when the calculation of small absolute dif-
fences in relative changes is difficult, it may be better to
assess iNPH walking performance in a single-task proce-
dure. If single-task walking is only slightly affected in pa-
tients with iNPH, the addition of dual-task walking para-
digms may help to avoid ceiling effects for the LP results.

Temporal Characteristics of Gait Improvement in iNPH
After LP

The improved walking of patients with iNPH after LP
is a transient phenomenon. An earlier study provided evi-
dence of improvement within the first 24 hours after LP.34
however, subsequent time points more than 24 hours after
LP were not investigated. Our study is the first system-
atic investigation of the time course of gait improvement
within the first 72 hours after LP. The results of the single-
task and dual-task walking assessments indicated that the
maximum gait improvement can be detected 24–72 hours
after LP. Nearly half of the objective responders accord-
ing to our definition of a responder status would have
been missed within the first 24 hours after LP. This find-
ing indicates that assessment of gait speed changes within
the first 24 hours after LP is susceptible to false-negative
results. Apart from the gradual improvement over 48–72
hours, the inner-subject consistency for subsequent mea-
surements was high. Only 2 patients had conflicting results
over the time span measured. Thus the improvement in
walking speed reflects a robust outcome measure of the
LP effect.

There is evidence that the extent of gait improvement
after LP corresponds to the extent of the benefit after shunt
surgery.12,18 This association was present in all patients
with iNPH who had undergone CSF removal therapies, ei-
either shunt surgery or repeated LPs. Significant correlations
between the LP response and therapy outcomes, however,
were only present for gait assessments at late time points
(that is, 48–72 hours after LP). This finding further indi-
cates that the delayed improvement in gait velocity after a
single LP could have higher predictive power than the re-
results of early assessments. Accordingly, clinicians should
measure the effects on walking performance after LP at
the time of maximum change to adequately estimate the
capacity for improvement after therapy.

Pathophysiological models of the gait disorder in iNPH
suggest a direct compression or deformation of the motor
fibers in the medial portion of the corona radiata.35 The
removal of CSF may inhibit the pathological high pressure
gradients in the lateral and third ventricles and the sylvian
fissures,22 which could lead to a decompression of frontal
and/or mesencephalic fibers of motor or premotor areas.
Other studies provide evidence for increases in regional
blood flow in different brain areas of patients with iNPH
after LP.3,11,20,31,45 These mechanisms would explain an im-
mediate release of symptoms after CSF removal. In the
current study, 8 patients showed slight gait improvements
immediately after LP. Moreover, the observed significant
correlation between the extent of lateral ventricle enlarge-
ment (measured by the EI) and early gait improvement
further supports the pressure-related symptom release in
iNPH. However, the current study also has implications
for delayed alternative and/or complementary pathophysi-
ological processes, which could be involved in the LP re-
response. Momjian et al. described the relationship between
reduced cerebral blood flow in the deep white matter of
patients with iNPH and impaired cerebral vascular auto-
regulation.29 Patients with iNPH were shown to have dis-
turbed autoregulation of cerebral arteries, especially near
the lateral ventricles. Impaired autoregulation of the ar-
teries could lead to edema and local ischemia, which were
thought to contribute to the emergence of the gait disor-
der in iNPH. Lumbar puncture–associated changes in the
CSF pressure gradient at the lateral ventricle walls and
in the surrounding white matter were shown to lead to a
shift in the watershed phenomenon of the regional blood
flow, thus improving vascular autoregulation in the peri-
ventricular areas.25,26 Moreover, changes in the interstitial
fluid pressure by CSF removal could decrease edema in the
periventricular tissue,24,41 thereby improving the clear-
ance of vasoactive and/or neurotoxic metabolites. Both
the improved vascular autoregulation and the enhanced
capacity for metabolic clearance may be the pathophysi-
ological substrates of delayed walking improvement in the
first days after LP.21

However, the current study was not designed to ade-
quately address the relationship between brain structure
and function in iNPH. Future investigations using neuro-
imaging and neurophysiological measurements in parallel
are required to directly address these pathophysiological
mechanisms.

Recommendations for a Clinical Gait Assessment During
the LP Procedure

Subjective estimations of gait improvement by patients
with iNPH are prone to false-negative and false-positive
ratings. Quantitative gait measurements can help to im-
prove the sensitivity and predictive value of the LP pro-
cedure: Gait velocity (and stride length) can be easily
assessed using a 35-ft (8-m) walking test, during which the physician records the ambulation time and the total steps. To assess walking speed capacity and the individual utilization of preferred speed, single-task walking with preferred speed and with maximally fast speed should be measured. We recommend performing a dual-task walking examination by adding an executive task (serial 7) and/or verbal fluency tasks (naming words) for patients with only minor impairments during single-task walking. Moreover, these conditions help to identify the extent of attentional resources spent on walking and simulate everyday mobility tasks.

The evaluation of post-LP measurements should be done not only 2–6 hours after the LP (to assess direct improvement) but also between 24 and 48 hours after the LP to avoid false-negative results and to estimate the real extent of walking improvement (Fig. 3).

**Limitations of the Study**

This study has several limitations. The study cohort of 24 patients with iNPH is relatively small for estimating correlations between the follow-up outcomes and the LP response. With the 18 patients who were treated with either shunt surgery or repeated LPs, we have reached a sufficient sample size for the Pearson’s correlations. For correlations with other outcome variables, such as quality of life, mobility measures, or independency, a further systematic study is necessary.

Moreover, the time points of follow-up measurements differed from 3 to 12 months. With respect to a possible dynamic disease course, this heterogeneity in follow-up times may lead to deficit interpretation of the follow-up results; however, only 2 patients (both with a non–CSF removal therapy) had a late follow-up measurement.

The analysis of associations between LP results and gait outcomes after shunt insertion or repeated LPs was performed with a very homogeneous follow-up period of 3–6 months after therapy.

**Conclusions**

The evaluation of post-LP measurements in iNPH should be done not only 2–6 hours after the LP (to assess direct improvement) but also between 24 and 48 hours after the LP to avoid false-negative results and to estimate the real extent of walking improvement.

**Acknowledgments**

This work was supported by the German research foundation (Deutsche Forschungsgemeinschaft, DFG JA 1087/1-1), the German Hertie Foundation, and the German Federal Ministry for Education and Science (BMBF, Nr. 01EO0901).

We thank Judy Benson for copyediting the manuscript.

**References**


42. Thomas G, McGirt MJ, Woodward G, Heidler J, Rigam-


Disclosures
The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.

Author Contributions
Conception and design: Schniepp, Trabold, Wuehr, Peraud, Brandt, Dieterich, Jahn. Acquisition of data: Schniepp, Trabold, Romagna, Akrami, Hesselbarth. Analysis and interpretation of data: all authors. Drafting the article: Schniepp, Trabold, Akrami, Hesselbarth, Wuehr, Peraud, Brandt, Dieterich, Jahn. Critically revising the article: Schniepp, Trabold, Akrami, Wuehr, Peraud, Brandt, Dieterich, Jahn. Reviewed submitted version of manuscript: Schniepp, Trabold. Approved the final version of the manuscript on behalf of all authors: Schniepp. Statistical analysis: Schniepp, Akrami, Hesselbarth, Wuehr, Jahn. Administrative/technical/material support: Schniepp, Romagna, Hesselbarth, Wuehr, Brandt, Dieterich, Jahn. Study supervision: Schniepp, Trabold, Romagna, Wuehr, Peraud, Brandt, Dieterich, Jahn.

Supplemental Information
Online-Only Content
Supplemental material is available with the online version of the article.


Correspondence
Roman Schniepp, Department of Neurology, University of Munich, Marchioninistrasse 15, Munich 81377, Germany. email: roman.schniepp@med.uni-muenchen.de.